Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.13325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Treatment of Acneiform Rash Induced by Trastuzumab as Neoadjuvant Therapy for Breast Cancer with a 595 nm Pulsed Dye Laser: A Case Report.
J Lasers Med Sci
November 2024
Department of Plastic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China.
Trastuzumab is now increasingly being used as a potent HER2 inhibitor in treating breast cancer, while acneiform rashes sometimes arise as skin-related side effects in patients undergoing treatment with HER2 inhibitors, and their specificity as drug-induced eruptions makes their management quite challenging. Pulsed dye laser (PDL) therapy has been utilized to treat a wide variety of vascular lesions, achieving excellent outcomes. A 595 nm PDL was used to treat a 38-year-old woman suffering from an acneiform rash induced by trastuzumab as neoadjuvant therapy for breast cancer.
View Article and Find Full Text PDFClinical Variant of Serpentine Supravenous Hyperpigmentation Following Subcutaneous Bortezomib Injection.
HCA Healthc J Med
December 2024
University of North Texas Health Science Center at Fort Worth, Fort Worth, TX.
Introduction: Bortezomib is a reversible proteasome inhibitor that is a first-line chemotherapeutic agent for multiple myeloma. Bortezomib can be administered intravenously or subcutaneously with similar efficacy. Subcutaneous administration has fewer side effects.
View Article and Find Full Text PDFCase report: Eczematous adverse drug reaction after selpercatinib treatment.
Front Oncol
December 2024
Dermatological Department, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
This study reports a 50-year-old patient presented with eczematous drug-eruption induced by selpercatinib after the treatment of non-small cell lung cancer (NSCLC). The patient has symmetric erythematous papules and plaques all over the body with dry, scaly skin accompanied by severe pruritus and visible scarring. After systemic treatment with glucocorticoids, the patient' skin lesions were reduced well.
View Article and Find Full Text PDFFlegel's Disease A Very Rare Skin Disease: A Case Report of Mother and Daughter in a Family.
Mymensingh Med J
January 2025
Dr Md Mostaque Mahmud, Associate Professor, Department of Dermatology & Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh; E-mail:
Flegel's disease (FD) or hyperkeratosis lenticularis perstans (HLP) is an extremely exceptional skin disease typified by hyper-keratotic papules usually found on the lower extremities. Only the histopathological study is the confirmatory test for diagnosis this disease. The treatment of Flegel's disease is not yet settled as a standard one.
View Article and Find Full Text PDFMilia En Plaque After Bullous Pemphigoid: An Unusual Sequela.
Cureus
November 2024
Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA.
We present the case of a 36-year-old paraplegic woman with a history of spinal cord injury who developed a generalized blistering rash, later diagnosed as bullous pemphigoid (BP). During her hospitalization, she was treated with prednisone and rituximab infusions, transitioning to maintenance therapy with topical steroids, doxycycline, and nicotinamide. A year later, she presented with concerns about a BP flare on her feet.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!